{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:51:53Z","timestamp":1790319113735,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jconrel.2021.04.034","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T23:54:42Z","timestamp":1619740482000},"page":"335-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3\u2032-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer"],"prefix":"10.1016","volume":"334","author":[{"given":"Sams M.A.","family":"Sadat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor M.","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Shire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forughalsadat","family":"Sanaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.R.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Paladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feridoun","family":"Karimi-Busheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajam S.","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank R.","family":"Jirik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis G.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Lavasanifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.04.034_bb0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/521S1a","article-title":"Colorectal cancer","volume":"521","author":"Brody","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jconrel.2021.04.034_bb0010","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/bjc.2013.212","article-title":"The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer","volume":"108","author":"Eklof","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2021.04.034_bb0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.onc.1207059","article-title":"PTEN mutations are common in sporadic microsatellite stable colorectal cancer","volume":"23","author":"Nassif","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2021.04.034_bb0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2015.00024","article-title":"PTEN: multiple functions in human malignant tumors","volume":"5","author":"Milella","year":"2015","journal-title":"Front. Oncol."},{"issue":"23","key":"10.1016\/j.jconrel.2021.04.034_bb0025","doi-asserted-by":"crossref","first-page":"11227","DOI":"10.1158\/0008-5472.CAN-05-2780","article-title":"Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer","volume":"65","author":"Frattini","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2021.04.034_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1471-2407-11-123","article-title":"Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors","volume":"11","author":"Naguib","year":"2011","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2021.04.034_bb0035","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cam4.592","article-title":"KRAS mutation in lung metastases from colorectal cancer: prognostic implications","volume":"5","author":"Ghidini","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.jconrel.2021.04.034_bb0040","first-page":"326","article-title":"Functions and regulation of the PTEN gene in colorectal cancer","volume":"3","author":"Molinari","year":"2013","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2021.04.034_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111765","article-title":"PTEN in colorectal cancer: shedding light on its role as predictor and target","volume":"11","author":"Salvatore","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jconrel.2021.04.034_bb0050","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1470-2045(10)70209-6","article-title":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","volume":"12","author":"De Roock","year":"2011","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2021.04.034_bb0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","article-title":"Tenets of PTEN tumor suppression","volume":"133","author":"Salmena","year":"2008","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jconrel.2021.04.034_bb0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMe0903044","article-title":"Synthetic lethality--a new direction in cancer-drug development","volume":"361","author":"Iglehart","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.jconrel.2021.04.034_bb0065","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.4161\/cc.8.19.9626","article-title":"Exploiting synthetic lethal interactions for targeted cancer therapy","volume":"8","author":"Reinhardt","year":"2009","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.jconrel.2021.04.034_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.gde.2010.10.009","article-title":"Searching for synthetic lethality in cancer","volume":"21","author":"Brough","year":"2011","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"5","key":"10.1016\/j.jconrel.2021.04.034_bb0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrd3374","article-title":"Harnessing synthetic lethal interactions in anticancer drug discovery","volume":"10","author":"Chan","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.jconrel.2021.04.034_bb0080","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-12-0939","article-title":"Genetic screening for synthetic lethal partners of polynucleotide kinase\/phosphatase: potential for targeting SHP-1-depleted cancers","volume":"72","author":"Mereniuk","year":"2012","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2021.04.034_bb0085","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-12-1093","article-title":"Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase\/phosphatase","volume":"12","author":"Mereniuk","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2021.04.034_bb0090","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.molcel.2005.02.012","article-title":"The molecular architecture of the mammalian DNA repair enzyme, polynucleotide kinase","volume":"17","author":"Bernstein","year":"2005","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.jconrel.2021.04.034_bb0095","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.tibs.2011.01.006","article-title":"Tidying up loose ends: the role of polynucleotide kinase\/phosphatase in DNA strand break repair","volume":"36","author":"Weinfeld","year":"2011","journal-title":"Trends Biochem. Sci."},{"issue":"19","key":"10.1016\/j.jconrel.2021.04.034_bb0100","doi-asserted-by":"crossref","first-page":"7739","DOI":"10.1158\/0008-5472.CAN-09-1805","article-title":"Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide kinase\/phosphatase","volume":"69","author":"Freschauf","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jconrel.2021.04.034_bb0105","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1021\/acs.molpharmaceut.8b00169","article-title":"Nanoencapsulation of novel inhibitors of PNKP for selective sensitization to ionizing radiation and irinotecan and induction of synthetic lethality","volume":"15","author":"Shire","year":"2018","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2021.04.034_bb0110","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2021.04.034_bb0115","first-page":"2112","article-title":"Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL","volume":"56","author":"Sparreboom","year":"1996","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2021.04.034_bb0120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2125.2004.02325.x","article-title":"Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL","volume":"59","author":"de Jonge","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2021.04.034_bb0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/bjc.1994.317","article-title":"Effects of Cremophor EL on distribution of taxol to serum lipoproteins","volume":"70","author":"Sykes","year":"1994","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2021.04.034_bb0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s002800050857","article-title":"Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL","volume":"43","author":"Ellis","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2021.04.034_bb0135","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.1997.15.5.1906","article-title":"Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer","volume":"15","author":"Gianni","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2021.04.034_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/tcrm.1.2.107.62910","article-title":"Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy","volume":"1","author":"Scripture","year":"2005","journal-title":"Ther. Clin. Risk Manag."},{"issue":"22","key":"10.1016\/j.jconrel.2021.04.034_bb0145","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1158\/1078-0432.CCR-05-1152","article-title":"Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel","volume":"11","author":"Henningsson","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2021.04.034_bb0150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1124\/dmd.110.035394","article-title":"Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model","volume":"39","author":"Fransson","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.jconrel.2021.04.034_bb0155","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"issue":"7","key":"10.1016\/j.jconrel.2021.04.034_bb0160","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.10397","article-title":"Amphiphilic block copolymers for drug delivery","volume":"92","author":"Adams","year":"2003","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2021.04.034_bb0165","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd4333","article-title":"Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery","volume":"13","author":"Torchilin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.jconrel.2021.04.034_bb0170","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1021\/acs.molpharmaceut.7b00188","article-title":"Overcoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic","volume":"14","author":"Houdaihed","year":"2017","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.jconrel.2021.04.034_bb0175","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s11095-008-9673-5","article-title":"Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells","volume":"25","author":"Xiong","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.04.034_bb0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biomaterials.2017.08.001","article-title":"Traceable PEO-poly(ester) micelles for breast cancer targeting: the effect of core structure and targeting peptide on micellar tumor accumulation","volume":"144","author":"Garg","year":"2017","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.jconrel.2021.04.034_bb0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/027245701753179811","article-title":"Production, characterization, and epitope mapping of monoclonal antibodies against human polydeoxyribonucleotide kinase","volume":"20","author":"Fanta","year":"2001","journal-title":"Hybridoma"},{"issue":"2","key":"10.1016\/j.jconrel.2021.04.034_bb0190","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/chem.200390049","article-title":"A three-component reaction for diversity-oriented synthesis of polysubstituted piperidines: solution and solid-phase optimization of the first tandem aza[4+2]\/allylboration","volume":"9","author":"Toure","year":"2003","journal-title":"Chemistry"},{"issue":"19","key":"10.1016\/j.jconrel.2021.04.034_bb0195","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.1158\/0008-5472.CAN-04-1767","article-title":"PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells","volume":"64","author":"Lee","year":"2004","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2021.04.034_bb0200","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"issue":"6","key":"10.1016\/j.jconrel.2021.04.034_bb0205","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/icb.2008.27","article-title":"Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model","volume":"86","author":"Molavi","year":"2008","journal-title":"Immunol. Cell Biol."},{"issue":"16","key":"10.1016\/j.jconrel.2021.04.034_bb0210","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1016\/j.biomaterials.2013.02.019","article-title":"Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity","volume":"34","author":"Shahin","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.04.034_bb0215","doi-asserted-by":"crossref","first-page":"20051","DOI":"10.1038\/srep20051","article-title":"Curcumin nanoformulation for cervical cancer treatment","volume":"6","author":"Zaman","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jconrel.2021.04.034_bb0220","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10549-015-3288-4","article-title":"Bcl2 and Ki67 refine prognostication in luminal breast cancers","volume":"149","author":"Chen","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.jconrel.2021.04.034_bb0225","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.7314\/APJCP.2015.16.4.1605","article-title":"Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance","volume":"16","author":"Zhou","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"6","key":"10.1016\/j.jconrel.2021.04.034_bb0230","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/jclinpath-2012-201085","article-title":"Ki67 and proliferation in breast cancer","volume":"66","author":"Pathmanathan","year":"2013","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.jconrel.2021.04.034_bb0235","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1535-6108(03)00307-6","article-title":"Restoring functions of tumor suppressors with small molecules","volume":"4","author":"Smukste","year":"2003","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2021.04.034_bb0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2021.04.034_bb0245","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1389450114666140106095151","article-title":"Targeting tumor suppressor networks for cancer therapeutics","volume":"15","author":"Guo","year":"2014","journal-title":"Curr. Drug Targets"},{"issue":"7035","key":"10.1016\/j.jconrel.2021.04.034_bb0250","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jconrel.2021.04.034_bb0255","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2021.04.034_bb0260","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.jconrel.2021.04.034_bb0265","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nantod.2012.01.002","article-title":"Polymeric micelle stability","volume":"7","author":"Owen","year":"2012","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2021.04.034_bb0270","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.colsurfb.2015.05.015","article-title":"Polymeric micelles based on poly(ethylene oxide) and alpha-carbon substituted poly(varepsilon-caprolactone): an in vitro study on the effect of core forming block on polymeric micellar stability, biocompatibility, and immunogenicity","volume":"132","author":"Garg","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"5","key":"10.1016\/j.jconrel.2021.04.034_bb0275","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1021\/acs.molpharmaceut.9b01043","article-title":"Synthesis and analysis of (64)cu-labeled GE11-modified polymeric micellar nanoparticles for EGFR-targeted molecular imaging in a colorectal cancer model","volume":"17","author":"Paiva","year":"2020","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2021.04.034_bb0280","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0192623310373776","article-title":"Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development","volume":"38","author":"Festing","year":"2010","journal-title":"Toxicol. Pathol."},{"issue":"25","key":"10.1016\/j.jconrel.2021.04.034_bb0285","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.jconrel.2021.04.034_bb0290","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1158\/0008-5472.CAN-08-2822","article-title":"Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan","volume":"68","author":"Nakajima","year":"2008","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.jconrel.2021.04.034_bb0295","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1541-7786.MCR-16-0108","article-title":"Olaparib, monotherapy or with ionizing radiation, exacerbates DNA damage in normal tissues: insights from a new p21 reporter mouse","volume":"14","author":"McMahon","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"39","key":"10.1016\/j.jconrel.2021.04.034_bb0300","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1038\/sj.onc.1206727","article-title":"Inactivating mutations of CASPASE-7 gene in human cancers","volume":"22","author":"Soung","year":"2003","journal-title":"Oncogene"},{"issue":"40","key":"10.1016\/j.jconrel.2021.04.034_bb0305","doi-asserted-by":"crossref","first-page":"28379","DOI":"10.1074\/jbc.274.40.28379","article-title":"Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7","volume":"274","author":"Germain","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2021.04.034_bb0310","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/1541-7786.MCR-09-0373","article-title":"Constitutive activation of caspase-3 and poly ADP ribose polymerase cleavage in fanconi anemia cells","volume":"8","author":"Lyakhovich","year":"2010","journal-title":"Mol. Cancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100208X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100208X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:00:47Z","timestamp":1759161647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592100208X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":62,"alternative-id":["S016836592100208X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.04.034","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3\u2032-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.04.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}